3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Glioblastoma
6
Gliosarcoma
5
Brain Neoplasms
5
Prostatic Neoplasms
4
Oligodendroglioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Glioma
3
Astrocytoma
3
Waldenstrom Macroglobulinemia
2
Lymphoma, B-Cell, Marginal Zone
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Interventions
Gemcitabine
97
130-nm albumin-bound paclitaxel
47
Albumin-Bound Paclitaxel
36
Oxaliplatin
27
Fluorouracil
26
Capecitabine
20
Taxes
19
Leucovorin
19
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Bevacizumab
12
fludarabine
11
Nivolumab
11
Cetuximab
11
Cisplatin
10
durvalumab
8
Radiotherapy
8
spartalizumab
7
aldesleukin
7
Erlotinib Hydrochloride
7
Drug Therapy
7
avelumab
6
Radiosurgery
6
Paclitaxel
6
irinotecan sucrosofate
5
folfirinox
5
Ipilimumab
5
Injections
5
ALT-803
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pancreatic Neoplasms
×
temsirolimus
×
Clear all
NCT02423954
2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2
Terminated
33 enrolled